Polymorphic sequence variants in medicine: A challenge and an opportunity

Clinical Medicine

Volumn 3, Issue 3, 2003, Pages 260-264

  Hodgson, Shirley V ^a,b   Popat, Sanjay ^c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c NONE

Author keywords

Alleles; Genetics; Penetrance; Pharmacogenetics; Polymorphism

Indexed keywords

APC PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOCHROME P450 2D6; DNA; THIOPURINE METHYLTRANSFERASE;

BIOBANK; CONFIDENTIALITY; DATA BASE; DIAGNOSTIC VALUE; DISEASE PREDISPOSITION; DNA DETERMINATION; DNA POLYMORPHISM; DRUG METABOLISM; EVALUATION; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEALTH CARE QUALITY; HUMAN; MEDICAL ETHICS; PENETRANCE; QUANTITATIVE ANALYSIS; REVIEW;

EID: 0038450134     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.3-3-260     Document Type: Review

References (37)

1. Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000;405:857-65.
2. Collins FS, Guyer MS, Charkravarti A. Variations on a theme: cataloging human DNA sequence variation. Science 1997;278:1580-1.
3. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, et al (the International SNP Map Working Group). A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001;409:822-3.
4. Otto A. Lyme vaccine linked to autoimmune arthritis. Pharmacy Today 2001;7:10.
5. Nowlan W. A rational view of insurance and genetic discrimination. Science 2002;297:195-6.
6. Stephenson J. Genetic test information fears unfounded. JAMA 1999;282:2197-8.
7. Rothenberg KH, Terry SE Human genetics. Before it's too late addressing fear of genetic information. Science 2002;297:196-7.
8. Rees J. Complex disease and the new clinical sciences. Science 2002; 296:698-701.
9. Caldwell J. The pharmacogenetic basis of adverse drug reactions. Int J Pharmaceut Med 2001;15:83-4.
10. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356:1667-71.
11. Roddam PL, Rollinson S, Kane E, Roman E et al. Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia. Pharmacogenetics 2000;10:605-15.
12. Wilson JF, Weale ME, Smith AC, Gratrix F et al. Population genetic structure of variable drug response. Nature Genet 2001;29:265-9.
13. Yancy CW, Fowler MB, Colucci WS, Gilbert EM et al. U.S. Carvedilol Heart Failure Study Group. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001;344:1358-65.
14. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344:1351-7.
15. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Ann Rev Pharmacol Toxicol 2001;41: 101-21.
16. Holgate ST, Lunnon MW. Pharmacogenetics Working Party: introduction. Int J Pharmaceut Med 2001;15:1563-6.
17. Shah RR. Regulatory aspects of integration of pharmacogenetics into drug development. Int J Pharmaceut Med 2001;15:67-69.
18. Rothstein MA, Epps PG. Ethical and legal implications of pharmacogenomics. Nat Rev Genet 2001;2:228-31.
19. Holmer AF. The pharmaceutical industry - to whom is it accountable? N Engl J Med 2000;343:1415.
20. Mrazek MF, Mossialos E. Increasing demand while decreasing costs of genetic medicines Lancet 2000;365:1784-5.
21. Houlston RS, Tomlinson IP. Detecting low penetrance genes in cancer: the way ahead. J Med Genet 2000;37:161-7.
22. Peto J, Houlston RS. Genetics and the common cancers. Eur J Cancer 2001;37(Suppl 8):S88-96.
23. Woodage T, King SM, Wacholder S, Hartge P et al. The APCI1307K allele and cancer risk in a community-based study of Ashkenazi Jews. Nature Genet 1998;20:62-5.
24. Gruber SB, Ellis NA, Rennert G, Offit K et al. BLM heterozygosity and the risk of colorectal cancer. Science 2002;297:2013.
25. Cotton SC, Sharp L, Little J, Brockton N. Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol 2000;151:7-32.
26. Moisio AL, Sistonen P, Mecklin JP, Jarvinen H, Peltomaki P. Genetic polymorphisms in carcinogen metabolism and their association to hereditary nonpolyposis colon cancer. Gastroenterology 1998;115: 1387-94.
27. Mucci LA, Wedren S,Tamimi RM, Trichopoulos D, Adami HO.The role of gene-environment interaction in the aetiology of human cancer: examples from cancers of the large bowel, lung and breast. J Intern Med 2001;249:477-93.
28. Houlston RS, Tomlinson IP. Polymorphisms and colorectal tumour risk. Gastroenterology 2001;121:282-301.
29. Todd JA. Human genetics. Tackling common disease. Nature 2001;411: 537-9.
30. Hampe J, Cuthbert A, Croucher PJ, Mirza MM et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001;357:1925-8.
31. Ogura Y, Bonen DK, Inohara N, Nicolae DL et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
32. Day IN, Wilson DI. Science, medicine, and the future: Genetics and cardiovascular risk. Br Med J 2001;323:1409-12.
33. Sijbrands EJ, Westendorp RG, Defesche JC, de Meier PH, et al. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. Br Med J 2001;322:1019-23.
34. Wald NJ, Hackshaw AK, Frost CD. When can a risk factor be used as a worthwhile screening test? Br Med J 1999;319:1562-5.
35. Abreu MT, Taylor KD, Lin YC, Hang T et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002;123:679-88.
36. Clarke A, English V, Harris H, Wells F. Ethical considerations. Int J Pharmaceut Med 2001;15:89-94.
37. Reilly PR, Boshar MF, Holtzman SH. Ethical issues in genetic research: disclosure and informed consent. Nature Genet 1997;15:16-20.